Stanford University
Showing 1,511-1,520 of 2,475 Results
-
Paul Milgrom
Shirley R. and Leonard W. Ely, Jr. Professor in the School of Humanities and Sciences, Professor of Economics, Senior Fellow at SIEPR and Professor, by courtesy, of Economics at the GSB and of Management Science and Engineering
BioPaul Milgrom is the Shirley and Leonard Ely professor of Humanities and Sciences in the Department of Economics at Stanford University and professor, by courtesy, in the Stanford Graduate School of Business and in the Department of Management Sciences and Engineering. Born in Detroit, Michigan on April 20, 1948, he is a member of both the National Academy of Sciences and the American Academy of Arts and Sciences and a winner of the 2008 Nemmers Prize in Economics, the 2012 BBVA Frontiers of Knowledge award, the 2017 CME-MSRI prize for Innovative Quantitative Applications, and the 2018 Carty Award for the Advancement of Science.
Milgrom is known for his work on innovative resource allocation methods, particularly in radio spectrum. He is coinventor of the simultaneous multiple round auction and the combinatorial clock auction. He also led the design team for the FCC's 2017 incentive auction, which reallocated spectrum from television broadcast to mobile broadband.
According to his BBVA Award citation: “Paul Milgrom has made seminal contributions to an unusually wide range of fields of economics including auctions, market design, contracts and incentives, industrial economics, economics of organizations, finance, and game theory.” As counted by Google Scholar, Milgrom’s books and articles have received more than 80,000 citations.
Finally, Milgrom has been a successful adviser of graduate students, winning the 2017 H&S Dean's award for Excellence in Graduate Education. -
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
D. Craig Miller, M.D.
Thelma and Henry Doelger Professor of Cardiovascular Surgery, Emeritus
Current Research and Scholarly InterestsCardiac and heart valve disease with experimental laboratory large animal projects focused on the investigation of left ventricular and cardiac mechanics, bioenergetics, and LV and mitral valve physiology and pathophysiology. Current thrust is aimed at understanding the mitral valve and subvalvular mitral apparatus and transmural LV wall strains, thickening, and myolaminar fiber-sheet mechanics.
Clinical research interests include thoracic aortic diseases (aortic dissection, aneurysm) and cardiac valvular disease, including surgical treatment, endovascular thoracic aortic stent-graft repair, mitral valve repair, and valve-sparing aortic root replacement. -
Arnold Milstein
Professor of Medicine (General Medical Discipline)
Current Research and Scholarly InterestsDesign national demonstration of innovations in care delivery that provide more with less. Informed by research on AI-assisted clinical workflow, positive value outlier analysis and triggers of loss aversion bias among patients and clinicians.
Research on creation of a national index of health system productivity gain. -
Paul Salomon Mischel
Fortinet Founders Professor and Professor, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.
